Akèy › Rabdomiyosakòm › Texas
Etid klinik pou Rabdomiyosakòm nan Texas
9 etid pou Rabdomiyosakòm ap chèche patisipan nan sit nan Texas.
Vil nan Texas
Tèks ofisyèl etid la (Anglè)
Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
- University of Texas - MD Anderson Cancer Center, Houston
Ap rekriteFaz 1
24 Months – 18 Years · Tout sèks · Mizajou Sep 25, 2026 · NCT06441331Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
- Children's Medical Center, Dallas
Ap rekriteFaz 1/2
Jiska laj 30 · Tout sèks · Mizajou Sep 3, 2026 · NCT06541262A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
- ak 2 plis
Ap rekriteFaz 3
Jiska laj 50 · Tout sèks · Mizajou Aug 25, 2026 · NCT07466316Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
- Texas Children's Hospital, Houston
Ap rekriteFaz 1
Laj 1 a 21 · Tout sèks · Mizajou Aug 6, 2026 · NCT04715191PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
- Texas Children's Hospital, Houston
Ap rekriteFaz 1/2
Laj 1 a 30 · Tout sèks · Mizajou Jul 22, 2026 · NCT06721689Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
- Cook Children's Medical Center, Fort Worth
Ap rekriteFaz 2
Jiska laj 22 · Tout sèks · Mizajou Jun 15, 2026 · NCT06023641VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors
- The University of Texas Southwestern Medical Center, Dallas
- Texas Children's Hospital, Houston
Ap rekriteFaz 1/2
6 Months – 30 Years · Tout sèks · Mizajou Jun 2, 2026 · NCT04796012HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
- Texas Children's Hospital, Houston
Ap rekriteFaz 1
Laj 1 a 25 · Tout sèks · Mizajou Jan 22, 2026 · NCT04995003Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
- Houston Methodist Hospital, Houston
Ap rekriteFaz 1
Jiska laj 21 · Tout sèks · Mizajou Nov 3, 2025 · NCT06198296Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.